US 12,187,724 B2
Pyrazolopyridine derivative having GLP-1 receptor agonist effect
Hitoshi Yoshino, Shizuoka (JP); Satoshi Tsuchiya, Shizuoka (JP); Atsushi Matsuo, Shizuoka (JP); Tsutomu Sato, Shizuoka (JP); Masahiro Nishimoto, Shizuoka (JP); Kyoko Oguri, Shizuoka (JP); Hiroko Ogawa, Shizuoka (JP); Yoshikazu Nishimura, Shizuoka (JP); Yoshiyuki Furuta, Kanagawa (JP); Hirotaka Kashiwagi, Shizuoka (JP); Nobuyuki Hori, Shizuoka (JP); Takuma Kamon, Shizuoka (JP); Takuya Shiraishi, Shizuoka (JP); Shoshin Yoshida, Shizuoka (JP); Takahiro Kawai, Shizuoka (JP); Satoshi Tanida, Shizuoka (JP); and Masahide Aoki, Shizuoka (JP)
Assigned to CHUGAI SEIYAKU KABUSHIKI KAISHA, Tokyo (JP)
Filed by Chugai Seiyaku Kabushiki Kaisha, Tokyo (JP)
Filed on Aug. 11, 2023, as Appl. No. 18/448,497.
Application 18/448,497 is a continuation of application No. 17/065,122, filed on Oct. 7, 2020, granted, now 11,814,381.
Application 17/065,122 is a continuation of application No. 15/759,872, granted, now 10,858,356, issued on Dec. 8, 2020, previously published as PCT/JP2017/034620, filed on Sep. 26, 2017.
Claims priority of application No. 2016-187605 (JP), filed on Sep. 26, 2016.
Prior Publication US 2023/0382912 A1, Nov. 30, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61K 31/437 (2006.01); A61K 31/444 (2006.01); A61K 31/4709 (2006.01); A61K 31/4725 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/5386 (2006.01); A61P 1/16 (2006.01); A61P 3/04 (2006.01); A61P 3/06 (2006.01); A61P 3/10 (2006.01); A61P 9/10 (2006.01); A61P 9/12 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); C07D 519/00 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 31/437 (2013.01); A61K 31/444 (2013.01); A61K 31/4709 (2013.01); A61K 31/4725 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/5386 (2013.01); A61P 1/16 (2018.01); A61P 3/04 (2018.01); A61P 3/06 (2018.01); A61P 3/10 (2018.01); A61P 9/10 (2018.01); A61P 25/16 (2018.01); A61P 25/28 (2018.01); C07D 519/00 (2013.01)] 3 Claims
 
1. A method for treating hypertension in a patient in need thereof comprising administering an effective amount of a compound having the following chemical structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.